お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
939994

市場スポットライト:肉腫 (サルコーマ)

Market Spotlight: Sarcoma

出版日: | 発行: Datamonitor Healthcare | ページ情報: 英文 55 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.53円
市場スポットライト:肉腫 (サルコーマ)
出版日: 2020年10月15日
発行: Datamonitor Healthcare
ページ情報: 英文 55 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の肉腫 (サルコーマ) 治療薬市場について調査分析し、主な上市薬・パイプライン薬、臨床試験、最近の動向、将来の動向、成功確率、特許情報、10ヶ年予測などについて、体系的な情報を提供しています。

目次

概要

要点

疾患の背景

  • サブタイプ

治療

  • 手術
  • 化学療法
  • 放射線治療
  • 標的療法

疫学

  • 疫学的疾患の定義

上市薬

パイプライン薬

最近の動向とアナリストの見解

近い将来の動向

主な規制の動向

成功確率

ライセンスと資産買収取引

親特許

収益機会

臨床試験情勢

  • スポンサー:ステータス別
  • スポンサー:フェーズ別
  • 最近の動向

参考文献

  • 処方情報

付録

目次
Product Code: DMKC0185529

This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, probability of success, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were approximately 430,300 incident cases of sarcoma worldwide, and forecasts that number to increase to 503,700 incident cases by 2028.

Worldwide, the majority of sarcoma cases were soft tissue and other extraosseous sarcomas (85%), while a smaller proportion were osteosarcomas and malignant bone tumors (15%).

The approved drugs in the sarcoma space focus on a wide variety of targets. These drugs are administered via the intravenous and oral routes.

The majority of industry-sponsored drugs in active clinical development for sarcoma are in Phase II. Therapies in development for sarcoma focus on a wide variety of targets. The majority of these therapies are administered via the oral and intravenous routes, with the remainder being intraocular, subretinal, subconjunctival, intradermal, intramuscular, intraarterial, intratumoral, topical, and subcutaneous formulations.

High-impact upcoming events for drugs in the sarcoma space comprise topline Phase II trial results for ADP-A2M4 and topline Phase Ib/II trial results for ABI-009.

The overall likelihood of approval of a Phase I sarcoma asset is 10%, and the average probability a drug advances from Phase III is 50%. Drugs, on average, take 9.5 years from Phase I to approval in the sarcoma space as well as in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for sarcoma have been in the early and mid-phases of development, with 90% of trials in Phase I-II, and only 10% in Phase III-IV.

The US has a substantial lead in the number of sarcoma clinical trials globally. France leads the major European markets, while Israel has the top spot in Asia.

Clinical trial activity in the sarcoma space is dominated by completed trials. Merck & Co and Novartis have the highest number of completed clinical trials for sarcoma, with 21 trials each.

Merck & Co leads industry sponsors with the highest overall number of clinical trials for sarcoma, followed by Bristol Myers Squibb and Novartis.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Surgery
  • Chemotherapy
  • Radiation therapy
  • Targeted therapies

EPIDEMIOLOGY

  • Epidemiological disease definition

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Keytruda for Sarcoma (September 20, 2020)
  • ADP-A2M4 for Sarcoma (May 29, 2020)
  • Tazverik for Sarcoma (December 18, 2019)
  • Tazverik for Sarcoma (December 16, 2019)
  • Bempegaldesleukin for Sarcoma (June 3, 2019)
  • Tazverik for Sarcoma (June 3, 2019)
  • Lartruvo for Sarcoma (June 2, 2019)
  • Hensify for Sarcoma (April 4, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Tazverik Accelerated Approval: Disease Rarity And Unmet Need Won Out Over Efficacy Concerns
  • Takara Bio's Mipetresgene Autoleucel Receives Orphan Regenerative Medicine Designation For Synovial Sarcoma
  • Tazverik Nabs Accelerated Approval Despite FDA Concerns About Confirmatory Trial
  • Adaptimmune SPEARs An RMAT For Synovial Sarcoma

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • PharmaMar Licenses Yondelis To TTY In Three Asian Markets
  • Deals Shaping The Medical Industry, February 2020
  • STA Acquires Australian, Asian Rights To Yondelis

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of sarcoma, 2019-28
  • Figure 2: Incident cases of sarcoma, by age, 2019
  • Figure 3: Incident cases of sarcoma, by tumor type, 2019
  • Figure 4: Overview of pipeline drugs for sarcoma in the US
  • Figure 5: Pipeline drugs for sarcoma, by company
  • Figure 6: Pipeline drugs for sarcoma, by drug type
  • Figure 7: Pipeline drugs for sarcoma, by classification
  • Figure 8: Keytruda for Sarcoma (September 20, 2020): Phase II - AcSe
  • Figure 9: Bempegaldesleukin for Sarcoma (June 3, 2019): Phase II - w/Nivolumab
  • Figure 10: Tazverik for Sarcoma (June 3, 2019): Phase II - INI1-Negative Tumors
  • Figure 11: Lartruvo for Sarcoma (June 2, 2019): Phase III - ANNOUNCE (w/Doxorubicin)
  • Figure 12: Key upcoming events in sarcoma
  • Figure 13: Probability of success in the sarcoma pipeline
  • Figure 14: Clinical trials in sarcoma
  • Figure 15: Top 10 drugs for clinical trials in sarcoma
  • Figure 16: Top 10 companies for clinical trials in sarcoma
  • Figure 17: Trial locations in sarcoma
  • Figure 18: Sarcoma trials status
  • Figure 19: Sarcoma trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of sarcoma, 2019-28
  • Table 2: Marketed drugs for sarcoma
  • Table 3: Pipeline drugs for sarcoma in the US
  • Table 4: Keytruda for Sarcoma (September 20, 2020)
  • Table 5: ADP-A2M4 for Sarcoma (May 29, 2020)
  • Table 6: Tazverik for Sarcoma (December 18, 2019)
  • Table 7: Tazverik for Sarcoma (December 16, 2019)
  • Table 8: Bempegaldesleukin for Sarcoma (June 3, 2019)
  • Table 9: Tazverik for Sarcoma (June 3, 2019)
  • Table 10: Lartruvo for Sarcoma (June 2, 2019)
  • Table 11: Hensify for Sarcoma (April 4, 2019)
  • Table 12: Historical global sales, by drug ($m), 2015-19
  • Table 13: Forecasted global sales, by drug ($m), 2020-24
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.